(Updated - December 7, 2023 4:29 AM EST)

Jefferies analyst Andrew Tsai upgraded VistaGen Therapeutics (NASDAQ: VTGN) from Hold ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE